SphingoTec has established an extended intellectual property portfolio covering markers for acute care conditions such as sepsis, acute heart failure and acute kidney injury.
Diese Seite richtet sich ausschließlich an Beschäftigte im Gesundheitswesen. Wenn Sie fortfahren, bestätigen Sie, dass Sie im Gesundheitswesen tätig sind.
Four units at the University Hospital Heidelberg and Heidelberg Kidney Center implement Proenkephalin (penKid) in a pilot biomarker-based treatment approach to diagnose AKI faster and monitor it more…
International medical experts discussed the latest developments in diagnostic and therapeutic innovations for advancing precision medicine in critically ill patients during the 4th Scientific…
New findings support the clinical value of the biomarker bio-ADM for triaging sepsis patients in ED, exceeding the prognostic performance of routine biomarkers. So far, the predictive potential of…
Thank you for your request
We will reach out to you shortly.
SphingoTec GmbH Neuendorfstr. 15 16761 Hennigsdorf
Phone: 03302 205650 Email: info[at]sphingotec.com
SphingoTec develops and markets innovative in vitro diagnostic (IVD) tests for novel and proprietary blood-based protein biomarkers. These tests allow for the diagnosis, outcome prediction, and…
Next to our Nexus IB10 automated and portable immunoassay system we also provide customized MTP assays and testing services to fulfill the specific requirements of our customers.
Jörg Menten, previously acting as Chief Commercial Officer of the company, will focus on successfully commercializing the biomarker-based diagnostics that address high unmet needs in critical care…
